as 12-18-2024 12:32pm EST
Bone Biologics Corp is a healthcare solutions provider based in the United States. As a biotechnology firm, it engages its efforts in developing therapeutics to aid bone regeneration. The company's portfolio comprises its lead product, NELL-1, which is a bone void filler. Bone Biologics' technology has applications in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.
Founded: | 2004 | Country: | United States |
Employees: | N/A | City: | BURLINGTON |
Market Cap: | 3.3M | IPO Year: | N/A |
Target Price: | N/A | AVG Volume (30 days): | 108.0K |
Analyst Decision: | N/A | Number of Analysts: | N/A |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -7.27 | EPS Growth: | N/A |
52 Week Low/High: | $0.80 - $10.56 | Next Earning Date: | 11-14-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
BBLG Breaking Stock News: Dive into BBLG Ticker-Specific Updates for Smart Investing
Zacks Small Cap Research
a month ago
Business Wire
2 months ago
MT Newswires
3 months ago
Business Wire
3 months ago
Medical Device Network
4 months ago
Zacks Small Cap Research
4 months ago
Business Wire
5 months ago
Zacks Small Cap Research
5 months ago
The information presented on this page, "BBLG Bone Biologics Corp - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.